St. Cloud Hospital
- Type
- Teaching hospital
- Where
- SARTELL, MN
- Medicare CCN
- 240036
- Received
- $940,987 in 127 records, 2024 ($5,836 general, $935,151 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: St. Cloud Hospital Fuzzy (name and state)
- Business registration: St. Cloud Hospital DBA St. Benedict's Senior Community - Chateau Waters Fuzzy (name and state)
- Nonprofit contractor: St Cloud Hospital Fuzzy (name and state)
- Nonprofit: ST CLOUD HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 11 | $5,836 |
| 2024 | Research payment | 116 | $935,151 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Edwards Lifesciences Corporation | 19 | $276,535 | 2024 |
| ENDOTRONIX, INC. | 1 | $213,134 | 2024 |
| Medtronic, Inc. | 31 | $204,743 | 2024 |
| Boston Scientific Corporation | 28 | $134,892 | 2024 |
| PFIZER INC. | 15 | $32,584 | 2024 |
| Abbott Laboratories | 11 | $18,392 | 2024 |
| Eli Lilly and Company | 2 | $12,684 | 2024 |
| Amgen Inc. | 2 | $11,478 | 2024 |
| AngioDynamics, Inc. | 1 | $10,976 | 2024 |
| Novartis Pharmaceuticals Corporation | 1 | $7,245 | 2024 |
| Acerta Pharma LLC | 2 | $5,841 | 2024 |
| AstraZeneca UK Limited | 1 | $4,893 | 2024 |
| Stryker Corporation | 6 | $3,305 | 2024 |
| Linvatec Corporation | 2 | $1,811 | 2024 |
| AstraZeneca Pharmaceuticals LP | 1 | $1,000 | 2024 |
| ABIOMED | 1 | $750 | 2024 |
| Genentech USA, Inc. | 1 | $500 | 2024 |
| Solventum Corporation | 2 | $220 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 116 | $935,151 |
| Long term medical supply or device loan | 5 | $4,656 |
| Debt forgiveness | 5 | $679 |
| Space rental or facility fees (teaching hospital only) | 1 | $500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | ENDOTRONIX, INC. | $213,134 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2024 |
| 2024-12-31 | Medtronic, Inc. | $14,543 | Research payment | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-12-31 | Stryker Corporation | $1,802 | Long term medical supply or device loan | In-kind items and services | CASCADIA INTERBODY SYSTEM Device, SPINE | 2024 | |
| 2024-12-31 | Stryker Corporation | $957 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Linvatec Corporation | $475 | Long term medical supply or device loan | In-kind items and services | LINVATEC ARTHROSCOPY Device, ORTHOPEDIC SURGERY | 2024 | |
| 2024-12-31 | Stryker Corporation | $272 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $155 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $86 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Stryker Corporation | $32 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-16 | Edwards Lifesciences Corporation | $6,067 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-12-16 | Medtronic, Inc. | $4,507 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-12-12 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2024 |
| 2024-12-12 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $1,166 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $410 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-12-10 | Boston Scientific Corporation | $231 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2024 |
| 2024-12-06 | Medtronic, Inc. | $3,407 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-06 | Medtronic, Inc. | $1,749 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-05 | Edwards Lifesciences Corporation | $5,579 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-11-25 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-11-21 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-11-19 | Boston Scientific Corporation | $2,707 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-11-12 | Boston Scientific Corporation | $560 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-11-07 | Edwards Lifesciences Corporation | $10,340 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-10-24 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-10-24 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-10-21 | Abbott Laboratories | $9,218 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-10-15 | Boston Scientific Corporation | $5,617 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-10-10 | Genentech USA, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-10-08 | Boston Scientific Corporation | $191 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-10-03 | Edwards Lifesciences Corporation | $12,264 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-10-03 | Edwards Lifesciences Corporation | $7,892 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-09-30 | Edwards Lifesciences Corporation | $40,371 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-09-30 | PFIZER INC. | $12,500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2024 |
| 2024-09-19 | Medtronic, Inc. | $4,306 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-09-17 | Boston Scientific Corporation | $1,337 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-09-12 | Edwards Lifesciences Corporation | $12,797 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-09-12 | Edwards Lifesciences Corporation | $12,522 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-09-05 | Medtronic, Inc. | $1,470 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-09-05 | Medtronic, Inc. | $1,022 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-09-05 | Medtronic, Inc. | $954 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-09-02 | Medtronic, Inc. | $750 | Research payment | Cash or cash equivalent | COBALT DR MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | Crome/Cobalt Respiration | 2024 |
| 2024-08-19 | Abbott Laboratories | $494 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study | 2024 |
| 2024-08-13 | Medtronic, Inc. | $15,824 | Research payment | Cash or cash equivalent | COBALT DR MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | Crome/Cobalt Respiration | 2024 |
| 2024-08-13 | Boston Scientific Corporation | $970 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-08-13 | Boston Scientific Corporation | $384 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2024 |
| 2024-07-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2024 |
| 2024-07-29 | Abbott Laboratories | $360 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2024 |
| 2024-07-26 | Solventum Corporation | $120 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-07-26 | Solventum Corporation | $100 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-07-23 | Boston Scientific Corporation | $1,770 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-07-23 | Abbott Laboratories | $1,198 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2024 |
| 2024-07-23 | Boston Scientific Corporation | $384 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2024 |
| 2024-07-18 | Medtronic, Inc. | $2,835 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2024 |
| 2024-07-17 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-07-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-07-12 | Abbott Laboratories | $442 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, VASCULAR | ECLIPSE | 2024 |
| 2024-07-02 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2024 |
| 2024-06-27 | Medtronic, Inc. | $63,598 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-06-24 | Edwards Lifesciences Corporation | $32,303 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2024 | |
| 2024-06-24 | Edwards Lifesciences Corporation | $9,100 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2024 | |
| 2024-06-19 | Medtronic, Inc. | $1,249 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-06-19 | Medtronic, Inc. | $795 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-06-19 | Medtronic, Inc. | $477 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-06-18 | Boston Scientific Corporation | $2,373 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-06-17 | Medtronic, Inc. | $7,920 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-06-13 | Boston Scientific Corporation | $22,916 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | EchoPixel Holographic 3D CTA of Watchman FLX at 45 days and 1 year Post Implant | 2024 |
| 2024-06-13 | Boston Scientific Corporation | $20,875 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | EchoPixel Holographic 3D CTA of Watchman FLX at 45 days and 1 year Post Implant | 2024 |
| 2024-06-13 | Boston Scientific Corporation | $20,875 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | EchoPixel Holographic 3D CTA of Watchman FLX at 45 days and 1 year Post Implant | 2024 |
| 2024-06-11 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | Step and Walking Pattern From Cardiac Monitor Study | 2024 |
| 2024-05-28 | Boston Scientific Corporation | $6,243 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-05-28 | Edwards Lifesciences Corporation | $2,456 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-05-28 | Boston Scientific Corporation | $1,034 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | Step and Walking Pattern From Cardiac Monitor Study | 2024 |
| 2024-05-21 | Medtronic, Inc. | $4,899 | Research payment | Cash or cash equivalent | COBALT DR MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | Crome/Cobalt Respiration | 2024 |
| 2024-05-09 | Edwards Lifesciences Corporation | $11,737 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-05-09 | Edwards Lifesciences Corporation | $3,992 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-05-09 | Linvatec Corporation | $1,335 | Long term medical supply or device loan | In-kind items and services | VISICLEAR Device, GENERAL SURGERY | 2024 | |
| 2024-04-26 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-04-25 | Medtronic, Inc. | $6,928 | Research payment | Cash or cash equivalent | COBALT DR MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | Crome/Cobalt Respiration | 2024 |
| 2024-04-22 | Edwards Lifesciences Corporation | $22,019 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2024 | |
| 2024-04-22 | Boston Scientific Corporation | $5,138 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-04-22 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2024 |
| 2024-04-22 | Boston Scientific Corporation | $191 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-04-19 | Amgen Inc. | $5,363 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2024 |
| 2024-04-18 | Medtronic, Inc. | $8,767 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2024 |
| 2024-04-17 | Abbott Laboratories | $50 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2024 |
| 2024-04-16 | Acerta Pharma LLC | $440 | Research payment | Cash or cash equivalent | a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in comb | 2024 | |
| 2024-04-03 | Medtronic, Inc. | $33,978 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-04-01 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-03-28 | AstraZeneca Pharmaceuticals LP | $1,000 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2024 |
| 2024-03-26 | Amgen Inc. | $6,115 | Research payment | In-kind items and services | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2024 |
| 2024-03-25 | Edwards Lifesciences Corporation | $65,798 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2024 | |
| 2024-03-25 | AstraZeneca UK Limited | $4,893 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Le | 2024 |
| 2024-03-18 | Boston Scientific Corporation | $7,780 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-03-18 | Boston Scientific Corporation | $1,400 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-03-14 | Medtronic, Inc. | $2,612 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-03-14 | Medtronic, Inc. | $1,311 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-03-14 | Medtronic, Inc. | $318 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-03-13 | Medtronic, Inc. | $5,000 | Research payment | Cash or cash equivalent | COBALT DR MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | Crome/Cobalt Respiration | 2024 |
| 2024-03-04 | AngioDynamics, Inc. | $10,976 | Research payment | Cash or cash equivalent | ALPHAVAC Device, VIT | APEX | 2024 |
| 2024-03-01 | Novartis Pharmaceuticals Corporation | $7,245 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-02-29 | Edwards Lifesciences Corporation | $16,555 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2024 | |
| 2024-02-29 | Edwards Lifesciences Corporation | $3,359 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-02-29 | Edwards Lifesciences Corporation | $378 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2024 | |
| 2024-02-26 | Medtronic, Inc. | $250 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2024 |
| 2024-02-20 | Boston Scientific Corporation | $6,614 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-02-19 | Abbott Laboratories | $988 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2024 |
| 2024-02-15 | PFIZER INC. | $2,030 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-15 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-02-14 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2024 |
| 2024-02-12 | ABIOMED | $750 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | ECP | 2024 |
| 2024-02-12 | Boston Scientific Corporation | $560 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-02-08 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA | 2024 | |
| 2024-02-06 | Medtronic, Inc. | $407 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-02-05 | Boston Scientific Corporation | $17,754 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | Step and Walking Pattern From Cardiac Monitor Study | 2024 |
| 2024-01-29 | Abbott Laboratories | $2,531 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2024 |
| 2024-01-29 | Medtronic, Inc. | $2,440 | Research payment | Cash or cash equivalent | ONYX FRONTIER Device, Stents | PSR-Coronary | 2024 |
| 2024-01-25 | Eli Lilly and Company | $180 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2024 | |
| 2024-01-23 | Acerta Pharma LLC | $5,401 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in | 2024 |
| 2024-01-22 | Boston Scientific Corporation | $3,654 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2024 |
| 2024-01-22 | Abbott Laboratories | $360 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2024 |
| 2024-01-15 | Medtronic, Inc. | $10,423 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-01-09 | Eli Lilly and Company | $12,503 | Research payment | Cash or cash equivalent | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Sartell, MN, county Stearns County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Sartell, MN | County Stearns County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 19,758 | 160,865 | 5,739,445 |
| Population, 2020 census P1 | 19,351 | 158,292 | 5,706,494 |
| Median age B01002 | 34.8 | 35.1 | 38.8 |
| Under 18 B01001 | 29.2% | 23.6% | 22.9% |
| 65 and over B01001 | 15.1% | 16.1% | 17.3% |
| Households B11001 | 7,630 | 61,403 | 2,307,955 |
| Foreign born B05002 | 4.2% | 7.9% | 8.7% |
| Median household income B19013 | $84,131 | $77,066 | $89,062 |
| Median family income B19113 | $117,973 | $99,842 | $113,993 |
| Per capita income B19301 | $42,415 | $38,286 | $48,237 |
| Poverty rate B17001 | 7.4% | 12.9% | 9.3% |
| Unemployment rate B23025 | 2.2% | 4.1% | 4.1% |
| Civilian labor force B23025 | 10,639 | 88,499 | 3,119,042 |
| Mean commute (minutes) B08013 | 18.8 | 21.7 | 22.7 |
| Bachelor's degree or higher B15003 | 40.9% | 28.8% | 39.4% |
| Housing units B25001 | 7,726 | 66,625 | 2,545,030 |
| Owner-occupied B25003 | 61.8% | 67.9% | 72.2% |
| Renters B25003 | 38.2% | 32.1% | 27.8% |
| Median home value B25077 | $297,300 | $273,400 | $329,300 |
| Median gross rent B25064 | $1,275 | $1,068 | $1,280 |
| White, not Hispanic B03002 | 85.1% | 80.2% | 75.9% |
| Black B03002 | 4.6% | 9.0% | 6.9% |
| Hispanic or Latino B03002 | 3.1% | 4.8% | 6.4% |
| Asian B03002 | 1.7% | 1.9% | 5.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Sartell, MN.
Comments